Latest Innovation News

ITM Isotope Technologies Munich SE and Radiopharm Theranostics have entered a strategic supply agreement for the critical radioisotope Lutetium-177, underpinning Radiopharm’s clinical development of targeted cancer therapies.

Vection Technologies has partnered with Laerdal Italia to integrate XR and AI solutions into healthcare simulation, aiming to generate $1.7 million in revenue over three years and expand across Europe.

Anson Resources has negotiated a pioneering scaled royalty structure for its Green River Lithium Project in Utah, reducing the previous flat 5% rate to a sliding scale tied to lithium prices. This move enhances project viability and investment certainty amid evolving regulatory reforms.

Gentrack reported a solid 9.8% revenue increase to NZ$112 million in HY25, driven by recurring revenue growth and international expansion, while net profit after tax surged 34.7%. The company’s outlook remains optimistic as it targets FY25 revenue above NZ$230 million and deeper market penetration across Asia, Europe, and the Middle East.

Gentrack Group Limited reported a solid 9.8% revenue increase to NZ$112 million in the first half of FY25, powered by strong recurring revenue growth in utilities and a surge in its airports division, Veovo. Net profit after tax jumped 34.7%, supported by currency gains and a lower tax rate.

Gentrack Group Ltd reported a robust 9.8% revenue increase and a 34.7% jump in net profit for the first half of FY25, driven by strong recurring revenues and strategic global expansion.

Osteopore Limited has increased its capital raise by drawing down an additional A$500,000 on its Tranche 1 redeemable convertible notes, bringing total subscriptions to A$3.5 million. The funds will support ongoing operations and future growth initiatives.

Dicker Data announces the departure of co-founder David Dicker from CEO and Chairman roles, transitioning leadership to a seasoned executive team under co-founder Fiona Brown’s Executive Chairmanship.

Cynata Therapeutics confirms that the recent FDA orphan-drug exclusivity granted to Ryoncil® will not block approval of its CYP-001 therapy, highlighting key differences in drug composition and patient indications.

Recce Pharmaceuticals has successfully raised A$8.4 million through an entitlement offer and placement to fund pivotal Phase 3 clinical trials, advancing its synthetic anti-infective pipeline towards commercialisation in 2026.

ECS Botanics is on track for a record-breaking FY25 harvest with a 50% production increase and new premium product launches, signaling strong growth and a positive cash flow outlook.

Etherstack plc has reported its highest ever half-year cash receipts, surpassing US$7 million in the first half of FY2025, signaling strong momentum and a promising revenue outlook for the year.